Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Curtis Jeffrey R.; Xie Fenglong; Yun Huifeng; Bernatsky Sasha; Winthrop Kevin L.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

【24h】

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

机译：托法替尼和生物治疗类风湿关节炎患者中疱疹病毒感染的现实世界比较风险

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective To evaluate the risks of herpes zoster (HZ) and herpes simplex virus (HSV) infection associated with tofacitinib compared with biologic agents among patients with rheumatoid arthritis (RA).

机译：目的评估风湿性关节炎（RA）患者与托法替尼相关的带状疱疹（HZ）和单纯疱疹病毒（HSV）感染与生物制剂相比的风险。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2016年第10期|共5页
作者
Curtis Jeffrey R.; Xie Fenglong; Yun Huifeng; Bernatsky Sasha; Winthrop Kevin L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
Infections; Rheumatoid Arthritis; Vaccination;

机译：感染;类风湿关节炎;疫苗接种;

相似文献

外文文献
中文文献
专利

1. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis [J] . Curtis Jeffrey R., Xie Fenglong, Yun Huifeng, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第10期

机译：托法替尼和生物治疗类风湿关节炎患者中疱疹病毒感染的现实世界比较风险
2. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study [J] . Chen Yi-Ming, Huang Wen-Nan, Wu Yi-Da, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第5期

机译：类风湿性关节炎患者乙型肝炎病毒感染的重新激活，接受TOFACITINIB：真实研究
3. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [J] . Rutherford Andrew I., Subesinghe Sujith, Hyrich Kimme L., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第6期

机译：生物治疗的类风湿性关节炎患者的严重感染：英国风湿病学生物制剂的结果为类风湿性关节炎
4. New candidate parameters for evaluation of cardiovascular risk in patients with rheumatoid arthritis [C] . V. O. Omelchenko, M. A. Korolev, E. A. Letyagina, 2017 International Multi-Conference on Engineering, Computer and Information Sciences . 2017

机译：类风湿关节炎心血管风险评估的新候选参数
5. Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [D] . Liu, Tasia 2017

机译：类风湿关节炎患者使用抗肿瘤坏死因子药物的感染预测因子
6. Real-World Comparative Risks of Herpes Virus Infections inTofacitinib and Biologic-Treated Rheumatoid Arthritis Patients [O] . Jeffrey R Curtis, Fenglong Xie, Huifeng Yun, -1

机译：疱疹病毒感染的现实世界比较风险托法替尼和生物治疗的类风湿关节炎患者
7. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study [O] . Teresa A. Simon, Maarten Boers, Marc Hochberg, 2019

机译：类风湿性关节炎患者的恶性肿瘤和感染的比较风险激发ABATACEPT与其他生物学：多数据库现实世界研究

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

摘要

著录项

相似文献

相关主题

期刊订阅